



COMMONWEALTH of VIRGINIA

Department of General Services
Division of Consolidated Laboratory Services

Denise M. Toney, Ph.D. (HCLD)
Director

600 North 5th Street
Richmond, Virginia 23219
804-648-4480
FAX 804-371-7973

CLSI recently updated M100 Performance Standards for Antimicrobial Susceptibility Testing. The updated M100 includes revised MIC breakpoints for Ciprofloxacin and Levofloxacin for Enterobacteriaceae and *Pseudomonas aeruginosa*. These updates impact the DCLS CRE/CRPA antimicrobial susceptibility testing (AST) program.

DCLS is committed to providing accurate and up-to-date results based on recognized AST standards and requirements. Effective 6/1/2019, the following changes will occur for CRE and CRPA isolates received for testing at DCLS:

1. DCLS will no longer report AST results for Levofloxacin.
2. CLSI revised MIC breakpoints will be reported for Ciprofloxacin. The table below details these breakpoint updates:

CLSI Revised MIC Breakpoints for Ciprofloxacin						
Organism Type	Susceptible		Intermediate		Resistant	
	Previous Breakpoint	Updated Breakpoint	Previous Breakpoint	Updated Breakpoint	Previous Breakpoint	Updated Breakpoint
Enterobacteriaceae	≤ 1	≤ 0.25	2	0.5	≥ 4	≥ 1
<i>Pseudomonas aeruginosa</i>	≤ 1	≤ 0.5	2	1	≥ 4	≥ 2

Updated testing instructions and information on CRE/CRPA testing can be found on the DCLS website under the “Hot Topics” link:

<https://dgs.virginia.gov/division-of-consolidated-laboratory-services/updates/hot-topics/>

For questions, please contact:

Dr. LaToya Griffin-Thomas
Emily Craig

804-648-4480 ext. 281
804-648-4480 ext. 392